2. Background and Procedural History
The shareholders and the Rights Agreement
Sinovac is a China-based biopharmaceutical company incorporated in Antigua and Barbuda. MW Gestion is an investment management firm whose portfolio included at least one fund holding Sinovac securities. The defendants included Li, his company 1Globe, relatives who had held leadership positions at 1Globe, and the “Chiang Li Family,” a designation allegedly used by Li in securities filings.
In March 2016, Sinovac adopted a Rights Agreement containing a “poison pill.” Under the agreement, a shareholder acquiring at least fifteen percent of Sinovac stock would become an “Acquiring Person.” That shareholder’s rights would become void, while other shareholders could receive additional shares that diluted the Acquiring Person’s ownership.
MW Gestion alleged that the defendants concealed their aggregate holdings through purchases across relatives’ accounts and changes of accounts near disclosure thresholds. According to the complaint, these practices avoided disclosure obligations under Section 13(d) of the Securities Exchange Act of 1934 and delayed activation of the poison pill. These were allegations evaluated at the pleading stage, not findings by the First Circuit that the defendants committed securities fraud.
Parallel proceedings and the trading suspension
In March 2018, Sinovac sued 1Globe in Delaware over whether it had become an Acquiring Person and in federal court in Massachusetts over alleged Section 13(d) disclosure violations. Shortly afterward, 1Globe brought proceedings in Antigua challenging, among other things, the Rights Agreement’s validity.
The Antigua High Court upheld the agreement in December 2018. In February 2019, Sinovac announced that 1Globe and allied shareholders had triggered the poison pill and authorized an exchange of rights for common and newly created preferred shares. NASDAQ then suspended trading in Sinovac stock. Trading remained suspended when this appeal was decided.
On May 13, 2020, the SEC issued a cease-and-desist order against Li and 1Globe concerning Section 13(d) violations. The order found that improper disclosures had deprived shareholders of information needed for fully informed investment decisions and imposed a collective $290,000 penalty. That order later became central to MW Gestion’s allegations—and to the limitations ruling against it.
The federal action and the foreign appeal
- December 2021: The Antiguan appellate court affirmed the decision upholding the Rights Agreement.
- February 2022: 1Globe received permission to appeal to the Judicial Committee of the Privy Council, Antigua’s highest appellate tribunal.
- August 16, 2022: MW Gestion filed this federal action.
- December 5, 2022: MW Gestion filed its first amended complaint.
- August 2023: The district court dismissed the securities claims as time-barred but allowed the contractual-interference claim to proceed.
- December 2023: The district court stayed the remaining claim pending resolution of the Antigua litigation.
- January 16, 2025: The Privy Council reversed the Antiguan appellate decision and held the Rights Agreement invalid.
- March 19, 2025: MW Gestion sought leave to file a second amended complaint, proposing a tortious-interference-with-business-relations claim that did not require a valid contract.
- April 23, 2025: The district court denied leave because MW Gestion had engaged in an unduly delayed “wait and see” approach.
The parties subsequently stipulated to dismissal with prejudice of the contractual-interference claim, while preserving MW Gestion’s challenges to the amendment ruling and dismissal of the securities claims.
4. Analysis: Legal Reasoning and Precedents Cited
A. The pleading-stage record
The court began by identifying the materials it could consider. Saccoccia v. United States, 955 F.3d 171 (1st Cir. 2020), supplied the framework: accept well-pleaded allegations as true and draw reasonable inferences in the plaintiff’s favor. Its quotation of SBT Holdings, LLC v. Town of Westminster, 547 F.3d 28 (1st Cir. 2008), reinforced that plaintiff-favorable approach.
Through Butler v. Balolia, 736 F.3d 609 (1st Cir. 2013), also quoted in Saccoccia v. United States, the court recognized that it could consider incorporated documents, public records, and judicially noticeable facts. This mattered because the dispute depended heavily on the SEC order and the history of foreign judicial proceedings. Considering those materials did not convert the appeal into a trial of the underlying misconduct.
B. Amendment: liberal permission does not excuse foreseeable delay
The governing standard
Federal Rule of Civil Procedure 15(a)(2) directs courts to “freely give leave” to amend “when justice so requires.” But that liberal policy operates within a discretionary framework.
Lowe v. Gagné-Holmes, 126 F.4th 747 (1st Cir. 2025), citing Palmer v. Champion Mortg., 465 F.3d 24 (1st Cir. 2006), established abuse-of-discretion review. An appellate court generally defers when the record supplies an adequate reason for denial, such as undue delay, bad faith, futility, or lack of diligence. The question was therefore not whether amendment might have been permissible, but whether denying it fell outside the district court’s legitimate discretion.
ACA Fin. Guar. Corp. v. Advest, Inc., 512 F.3d 46 (1st Cir. 2008), supplied both sides of the balance: Rule 15 reflects a liberal amendment policy, but plaintiffs cannot indefinitely reserve available allegations while awaiting developments. In that case, a deliberate eighteen-month wait after discovering additional evidence supported denial of amendment.
United States ex rel. Flanagan v. Fresenius Med. Care Holdings, Inc., 142 F.4th 25 (1st Cir. 2025), quoting Kader v. Sarepta Therapeutics, Inc., 887 F.3d 48 (1st Cir. 2018), emphasized district courts’ “significant latitude.” Together, these authorities prevented the liberal amendment policy from becoming an entitlement to revise a complaint whenever an earlier litigation strategy failed.
The central question: when was the need to amend reasonably apparent?
MW Gestion measured its delay from the Privy Council’s January 2025 decision to its March 2025 amendment motion. The court accepted the district court’s broader perspective: the potential need for an alternative theory was apparent much earlier because the existing contractual claim depended entirely on an agreement already under challenge.
United States ex rel. Flanagan v. Fresenius Med. Care Holdings, Inc. was particularly influential. There, denial was upheld when a plaintiff had known of the potential need to amend for two years but waited for a dismissal ruling. The relevant awareness was not certainty that the existing claim would fail; knowledge of the potential need for amendment could suffice.
Kader v. Sarepta Therapeutics, Inc. showed that a much shorter delay could also be undue. The plaintiffs there waited three months after an agency document became available, apparently awaiting a ruling on dismissal. Their subjective confidence in their existing complaint did not justify postponement. Applied here, confidence that the Privy Council would uphold the Rights Agreement did not excuse withholding an alternative claim.
Nikitine v. Wilmington Trust Co., 715 F.3d 388 (1st Cir. 2013), further supported denial where a plaintiff offered no good explanation for a nine-month delay and sought new liability theories based on previously pleaded facts. Its quotation of Tiernan v. Blyth, Eastman, Dillon & Co., 719 F.2d 1 (1st Cir. 1983), underscored the concern about “scrambling” to devise new theories without explaining why they were not advanced earlier.
MW Gestion’s proposed business-relations claim fit that concern. It did not depend on newly discovered misconduct. Counsel’s statement that the claim “continued” to be available reinforced the conclusion that the theory could have been asserted before the foreign appeal was resolved. The vulnerability became particularly consequential after dismissal of the securities claims left the Rights Agreement as the foundation of the sole surviving count.
Why Amyndas did not require amendment
MW Gestion’s strongest counterauthority was Amyndas Pharmaceuticals, S.A. v. Zealand Pharma A/S, 48 F.4th 18 (1st Cir. 2022). That decision stressed that undue delay is context-dependent and permitted plaintiffs to respond to dismissal by realigning previously stated facts. It rejected an unduly mechanical approach to elapsed time.
The First Circuit distinguished that precedent on three grounds:
- The defect was more obvious here. In Amyndas Pharmaceuticals, S.A. v. Zealand Pharma A/S, the original pleading’s failure to distinguish sufficiently between related entities was not so obvious that waiting for a judicial ruling was unreasonable. Here, a contractual-interference claim plainly depended on the validity of the very agreement being challenged abroad.
- There was no new supporting evidence here. The amendment in Amyndas Pharmaceuticals, S.A. v. Zealand Pharma A/S included new evidence as well as reorganized allegations. MW Gestion conceded that its proposed amendment involved no new evidence. The Privy Council changed the agreement’s legal status, not the factual basis of the proposed alternative claim.
- This was a second amendment request. The plaintiffs in Amyndas Pharmaceuticals, S.A. v. Zealand Pharma A/S sought their first amendment. MW Gestion had already amended once without adding the alternative theory. Drawing again on United States ex rel. Flanagan v. Fresenius Med. Care Holdings, Inc. and Kader v. Sarepta Therapeutics, Inc., the court treated prior opportunities to address deficiencies as relevant, though not decisive.
The distinction preserves room for legitimate amendments responding to new information or a nonobvious pleading defect. It also confirms that a newly adverse ruling does not necessarily restart the diligence inquiry.
The significance of the stay
MW Gestion argued that the defendants had caused earlier delays. Nevertheless, the First Circuit accepted the conclusion that MW Gestion had an earlier opportunity to assert the alternative claim, notwithstanding the later stay. The opinion does not establish that a party must violate a stay or that every stayed period automatically counts as culpable delay. Its point was that the risk and the available alternative theory predated the stay.
Because undue delay independently supported the ruling, the court expressly declined to decide the parties’ arguments about prejudice and futility. Thus, the affirmance neither establishes that the proposed claim was substantively defective nor resolves whether allowing it would have unfairly harmed the defendants.
C. Securities fraud: discovery of supporting facts, not completion of related proceedings
The limitations framework
The complaint asserted Section 10(b) claims under Rule 10b-5(b) and Rules 10b-5(a) and (c), together with a Section 20(a) claim against the individual defendants. Under 28 U.S.C. § 1658(b)(1), the relevant limitations period was two years after discovery of the facts constituting the violation.
Merck & Co. v. Reynolds, 559 U.S. 633 (2010), supplied the controlling discovery rule. The period begins when the plaintiff actually discovers the necessary facts or when a reasonably diligent plaintiff would have discovered them, whichever occurs first. The inquiry therefore includes constructive discovery; it is not limited to when the particular plaintiff says it understood its case.
FirstBank P.R., Inc. v. La Vida Merger Sub, Inc., 638 F.3d 37 (1st Cir. 2011), established de novo review of the limitations dismissal. Quoting Gorelik v. Costin, 605 F.3d 118 (1st Cir. 2010), it also supplied the demanding pleading-stage requirement: the allegations must “leave no doubt” that the claim is time-barred.
Why the SEC order was decisive
MW Gestion filed on August 16, 2022. Discovery before August 16, 2020 would therefore place its claims outside the two-year period. The court concluded that discovery occurred no later than May 2020 because the SEC order disclosed the alleged misconduct underlying the complaint.
The complaint itself provided the critical connection. It said that the “details of Defendants’ deceptive tactics” appeared in the order and characterized the order as revealing a deliberate plan to conceal ownership, avoid disclosure obligations, and evade the Rights Agreement. Those allegations showed that the order supplied the facts on which MW Gestion later relied.
The reasoning was document-specific. An SEC order addressing Section 13(d) violations is not automatically a finding of private securities fraud under Section 10(b), nor does every enforcement announcement necessarily disclose all facts needed for a private claim. Here, the plaintiff’s extensive reliance on this particular order established its significance for discovery.
Why suspended trading did not postpone accrual
MW Gestion argued that it could not adequately plead loss causation and damages while Sinovac’s shares remained suspended. Dura Pharms., Inc. v. Broudo, 544 U.S. 336 (2005), supplied the relevant definition of loss causation: the causal connection between a material misrepresentation and the loss.
The court identified an internal inconsistency. Trading remained suspended when MW Gestion filed its complaint, yet the complaint pleaded loss causation. If suspension made pleading impossible in 2020, MW Gestion did not explain why the same continuing suspension permitted pleading in 2022. Its assertion that it need not wait indefinitely for trading to resume further weakened its argument that resumption was indispensable.
The decision does not hold that loss causation is irrelevant to discovery. Rather, it rejects the particular claim of factual unavailability where the supposedly disabling condition remained unchanged when suit was eventually filed.
The same problem affected MW Gestion’s scienter argument. It claimed that related litigation addressed the defendants’ fraudulent intent, but its complaint already relied on the SEC order’s description of deliberate conduct. The court found no explanation for why a later judicial characterization of the alleged scheme was necessary to plead intent.
D. Equitable tolling: foreign litigation was not a filing barrier
Foss v. E. States Exposition, 149 F.4th 102 (1st Cir. 2025), established abuse-of-discretion review of the refusal to toll the limitations period. Through Vistamar, Inc. v. Fagundo-Fagundo, 430 F.3d 66 (1st Cir. 2005), and Abraham v. Woods Hole Oceanographic Inst., 553 F.3d 114 (1st Cir. 2009), it supplied two related requirements: tolling is reserved for exceptional circumstances, and circumstances beyond the plaintiff’s control must have precluded timely filing.
MW Gestion requested three months of tolling following the May 2020 SEC order while the Antigua litigation remained pending. But that litigation did not prevent a securities action based on the facts already disclosed. The court therefore distinguished external uncertainty about related litigation from an external obstacle that actually prevents filing.